Home About Cancer News Contact Cancer News
Home About Cancer News Contact Cancer News
Twitter

Posts Tagged ‘symposium’

« Older Entries

Moving On From Traditional Biopsies, Blood Tests Found To Provide Fuller Picture Of Mutations In Cancer

By on Tuesday, April 9th, 2013 | No Comments

A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators report at a special symposium of the American Association for Cancer Research annual meeting in Washington, April 6-10…

Read More...

Finding a Mesothelioma Specialist Can Make a Difference

By on Monday, March 11th, 2013 | No Comments

Presenters at this year’s Meso Foundation Symposium stressed the importance of working with a mesothelioma specialist.

Read More...

Genetic Research Focus at Meso Foundation Symposium

By on Friday, March 8th, 2013 | No Comments

Researchers like Michele Carbone, M.D. presented the latest findings in mesothelioma research on genetics at the 2013 Meso Foundation Symposium. Genetic predisposition and genetic treatment were the hottest topics.

Read More...

REMINDER: Mesothelioma Applied Research Foundation Symposium This Week

By on Monday, March 4th, 2013 | No Comments

The Mesothelioma Applied Research Foundation’s tenth annual Symposium is scheduled for March 7-8, in Las Vegas.  The two-day conference is an opportunity for the entire mesothelioma community, including patients, their families, caregivers and advocates, to come together to network and to learn the latest mesothelioma news. The primary theme for the Symposium this year is …

Read More...

ASCO-GU Meeting Highlights

By on Wednesday, February 20th, 2013 | No Comments

The 2013 Genitourinary Cancers Symposium was more about expansion of knowledge than major practice changers. In an interview with The Oncology Report, Dr. Nicholas Vogelzang touches upon this year’s major studies on GU cancers and predicts what’s in the store for the coming year. For more coverage of ASCO-GU, visit www.oncologyreport.com.

Read More...

Dr. Nicholas Vogelzang Discusses Radium-223 in Prostate Cancer

By on Tuesday, February 19th, 2013 | No Comments

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, discusses an updated analysis of the phase III ALSYMPCA trial that examined radium-223 dichloride in patients with castration-resistant prostate cancer (CRPC). For more from the GU Cancers Symposium, visit www.onclive.com

Read More...

Dr. Matthew Cooperberg on Earlier Treatment With Sipuleucel-T in Prostate Cancer

By on Monday, February 18th, 2013 | No Comments

Matthew Cooperberg, MD, MPH, Assistant Professor of Urology; Epidemiology & Biostatistics, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the earlier administration of treatment with sipuleucel-T (Provenge) for men with prostate cancer. For more from the GU Cancers Symposium, visit www.onclive.com

Read More...

Dr. Howard Scher on Corticosteroids During Treatment With Enzalutamide in mCRPC

By on Sunday, February 17th, 2013 | No Comments

Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Prostate and Urologic Cancers at Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) receiving treatment with enzalutamide. For more from the GU Cancers Symposium, visit www.onclive.com

Read More...

Dr. Abdenour Nabid on Shorter Duration of ADT in Prostate Cancer

By on Friday, February 15th, 2013 | No Comments

Abdenour Nabid, MD, associate professor at Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of androgen-deprivation therapy (ADT) to 36 months in men with high-risk, localized, prostate cancer. For more from the GU Cancers Symposium, visit www.onclive.com

Read More...

DAI provides potential imaging biomarker to indicate brain tumor response to radiation therapy

By on Tuesday, February 12th, 2013 | No Comments

Diffusion abnormality index (DAI) shows promise as an imaging biomarker to measure brain tumor response to radiation therapy, according to University of Michigan research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium. The study included 20 patients who had brain metastases and were treated with whole brain radiotherapy. The University of Michigan is home to the University of Michigan Comprehensive Cancer Center.

Read More...
« Older Entries